Offer - Urjas Oil for just ₹ 1 X
Zedocef CV 100 DT Tablet is a prescription drug, available for use as Tablet. Zedocef CV 100 DT Tablet also has some secondary and off-label uses. These are listed below.
The correct dosage of Zedocef CV 100 DT Tablet depends on the patient's age, gender, and medical history. The condition it has been prescribed for, and the route of administration also determine the right dosage. Detailed information has been provided in the dosage section.
Besides the aforementioned side effects, there are other adverse effects of Zedocef CV 100 DT Tablet as well, which are listed below. Such side effects of Zedocef CV 100 DT Tablet normally do not last long and go away once the treatment is completed. Consult your doctor if these side effects become worse or stay for a longer duration.
In addition, Zedocef CV 100 DT Tablet's effect is Mild during pregnancy and Moderate for lactating mothers. Warnings related to Zedocef CV 100 DT Tablet's effects on the liver, heart and kidney, if any, have been listed below.
Zedocef CV 100 DT Tablet is contraindicated in people with pre-existing medical conditions like Jaundice as it can result in adverse effects. Other contraindications of Zedocef CV 100 DT Tablet have been discussed in the sections ahead.
Drug interactions for Zedocef CV 100 DT Tablet have been reported in the medical literature. See below for a complete list.
In addition to the above precautions for Zedocef CV 100 DT Tablet, it is important to know that it is safe while driving, and is habit-forming.
Zedocef CV 100 DT Tablet is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
13 - 18 years (Adolescent) |
|
Adult |
|
Geriatric |
|
Is the use of Zedocef CV 100 DT Tablet safe for pregnant women?
Pregnant women can consume [medicine]. Though Zedocef CV has mild side effects when taken during pregnany
Is the use of Zedocef CV 100 DT Tablet safe during breastfeeding?
Zedocef CV can cause moderate side effects on breastfeeding women. If you feel its side effects, then stop taking this drug and consult your doctor. Take this medicine again only if your doctor advises to do so.
What is the effect of Zedocef CV 100 DT Tablet on the Kidneys?
There can be some harmful effects on your kidneys after taking Zedocef CV. If you witness any side effects, discontinue its use. Consult your medical practitioner, do as he/she suggests.
What is the effect of Zedocef CV 100 DT Tablet on the Liver?
Zedocef CV can have moderate side effects on the liver. If you notice any harmful effects then stop taking this drug right away. Consult your doctor before using this medicine again.
What is the effect of Zedocef CV 100 DT Tablet on the Heart?
Side effects of Zedocef CV rarely affect the heart.
If you are suffering from any of the following diseases, you should not take Zedocef CV 100 DT Tablet unless your doctor advises you to do so -
Is this Zedocef CV 100 DT Tablet habit forming or addictive?
No, there is no any evidence that Zedocef CV 100 DT Tablet is addictive.
Interaction between Food and Zedocef CV 100 DT Tablet
Taking Zedocef CV 100 DT Tablet with food is safe.
Interaction between Alcohol and Zedocef CV 100 DT Tablet
Information about the interaction of Zedocef CV 100 DT Tablet and alcohol is not currently available because this topic has not been researched yet.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Vantin® (cefpodoxime proxetil )
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-311